1. Introduction {#sec1}
===============

Microarray-based investigations of genome wide gene expression have become a popular method for the molecular characterisation of various tissue types. In molecular oncology prognosis-related genes could be identified concerning various cancer types \[[@B1]--[@B5]\]. Especially in colorectal carcinoma gene clusters related to metastasis, tumour recurrence or chemoradiation were described \[[@B4], [@B6]--[@B8]\]. Microarray analysis in most of these studies was not dependent on RNA amplification, as enough RNA could be isolated from the tumours. Whenever tissue is limited and a high-throughput analysis is in concern, amplification of RNA by *in vitro* transcription is essential. However, using amplification, one has to be sure that the RNA is amplified linear, meaning that gene expressions will be comparable between native and amplified RNA. This is necessary, as more and more data are generated with different methods, stored at the internet being available for the research community. Recently the limited comparability of gene expression profiles between studies using different techniques has been demonstrated \[[@B5]\]. However, there is an ongoing discussion if microarray data of non amplified and amplified RNA samples are comparable. The aim of our study was to evaluate to which extend (1) the microarray data based on amplified RNA are reproducible, (2) the expression data from amplified and native RNA are comparable, and (3) if tumour specific genes are affected by an amplification bias.

2. Material and Methods {#sec2}
=======================

2.1. Patients and Experimental Procedure {#sec2.1}
----------------------------------------

Primary tumours of four patients with colorectal carcinomas stage UICC IV resected at the Department of Surgery at the Friedrich-Alexander-University Erlangen-Nuremberg were chosen for the analysis. No patient received neoadjuvant treatment prior to surgery. By approval of the Ethical Committee of our University and by patient consent, conformity to the ethical guidelines for human research respecting the principles of the Declaration of Helsinki was provided. After tumour enrichment by cryotomy after manual dissection (CMD) RNA was isolated from each sample \[[@B9]\]. One part of the RNA of each sample was hybridized to the microarray without amplification; the other part underwent amplification prior to microarray hybridization ([Figure 1](#fig1){ref-type="fig"}). For validation purpose the microarray data of amplified RNA from 31 colon carcinoma samples stage UICC III versus the microarray data of not amplified RNA from 24 colon carcinoma samples were used. Patient selection, tissue workup, and amplification protocol were equally in each group.

2.2. Sample Workup and RNA Isolation {#sec2.2}
------------------------------------

The tissue was inserted into a cryotube (Roth, Karlsruhe, Germany) together with Tissue-Tek (Zakura, Zoeterwoude, Netherlands) and immediately shock frozen in liquid nitrogen after surgery and stored at −80°C until further workup. CMD was performed as recently described \[[@B9]\]. RNA isolation was performed in the same way from all four tissue samples using commercial kits (RNeasy-Kit, Qiagen, Hilden, Germany), following the manufacturers\' protocol. Each sample was added to the Qiagen spin column, and centrifuged to bind the RNA to the matrix. The column was washed with the buffers provided in the kit, and the RNA was finally eluted with distilled H~2~0. Within this procedure a DNAse (Qiagen, Hilden, Germany) digestion was included following the manufacturers\' suggestion. RNA quality and quantity was determined by the "Lab on a Chip" method (Bioanalyzer 2100, Agilent Technologies, Palo Alto, USA) following the manufacturers\' instructions \[[@B10]\]. A total of 50 ng to 100 ng of each RNA sample was loaded/well. The analyser allows for visual examination of both the 18S and 28S rRNA bands as measure of RNA integrity.

The 3′/5′-ratios for the housekeeping genes glycerinaldehyde-3-phosphatase (GAPDH) and ß-actin supplied by the GeneChip were used as further parameters for RNA quality and to exclude partial degradation. A 3′/5′-ratio below the value of 3 was regarded as an indicator for good RNA quality according to the manufacturers\' protocol (Affymetrix, Santa Clara, USA) \[[@B11]\].

2.3. RNA Amplification {#sec2.3}
----------------------

Amplification of RNA was performed with the Message Amp aRNA kit (Ambion, Austin (Tx), USA) according to the manufacturers\' instructions, using 200 ng of total RNA for each sample. Briefly, first strand cDNA syntheses were primed with the T/Oligo (dT) primer to synthesize cDNA with a T/promoter sequence from the poly (A) tails of massages by reverse transcription. The second strand cDNA synthesis converted cDNA with the T7 promoter primer into double-stranded DNA (dsDNA) template for transcription. Following a cDNA purification step an *in vitro* transcription was done, generating multiple copies of aRNA from the double-stranded cDNA templates. Finally, in another purification step, unincorporated NTPs, salts, enzymes, and inorganic phosphate were removed. In a second round, the additional amplification of the RNA sample was achieved. Besides using different primers for the second round, the same reagents and methodology were used. During this second round the biotin labelling of the probe took place before the *in vitro* transcription step. Hereunto, for each sample, 3.75 *μ*L of 10 mM biotin 11-CTP and 3.75 *μ*L of 10 mM biotin-16-UTP were added and the probe dried in a vacuum centrifuge concentrator.

2.4. Labelling of "Native" RNA and GeneChip Hybridization {#sec2.4}
---------------------------------------------------------

Biotin-labelled cRNA was generated by *in vitro* transcription as described previously and hybridized to the GeneChips (HG-U133A, Affymetrix) following the manufacturers\' instructions. For first-strand cDNA synthesis, 9 *μ*L (13.5 *μ*g) of total RNA were mixed with 1 *μ*L of a mixture of three polyadenylated control RNAs, 1 *μ*L 100 *μ*M T7-oligo-d(T)21-V primer (5′-GCATT AGCGGCCGCGAAA TTAATACGACTCACT ATA-GGGAGA(T)21V-3′), incubated at 70°C for 10 min and put on ice. Next, 4 *μ*L of 5x first strand buffer, 2 *μ*L 0.1 M DTT and 1 *μ*L 10 mM dNTPs were added and the reaction was preincubated at 42°C for 2 min. Then 2 *μ*L (200 U) Superscript II (Life Technologies, Karlsruhe, Germany) were added and incubation continued at 42°C for 1 hour. For second strand synthesis, 30 *μ*L of 5x second strand buffer, 91 *μ*L of RNAse-free water, 3 mL 10 mM dNTPs, 4 *μ*L (40 U) E. coli DNA polymerase I (Life Technologies), 1 *μ*L (12 U) E. coli ligase (TaKaRa Biomedical Europe, Gennevilliers, France), 1 *μ*L (2 U) RNAse H (TaKaRa) were added and the reaction was incubated at 16°C for 2 hours. Then, 2.5 mL (10 U) T4 DNA polymerase I (TaKaRa) were added at 16°C for 5 min. The reaction was stopped by adding 10 *μ*L 0.5 M EDTA, the double-stranded cDNA was extracted with phenol/chloroform and the aqueous phase was recovered by phase lock gel separation (Eppendorf, Hamburg, Germany). After precipitation, the cDNA was restored in 12 *μ*L of RNAse-free water. Five microliters of ds cDNA were used to synthesize biotinylated cRNA using the BioArray High Yield Transcript Labeling Kit (Enzo Diagnostics, NY, USA). Labelled cRNA was purified using the RNeasy mini kit (Qiagen, Hilden, Germany). Fragmentation of cRNA, hybridization to GeneChips, washing and staining as well as scanning of the arrays in the Gene Array scanner (Agilent) were performed as recommended by the Affymetrix Gene Expression Analysis Technical Manual. Signal intensities and detection calls for statistical analysis and hierarchical clustering were determined using the GeneChip 5.0 software.

2.5. Statistics {#sec2.5}
---------------

Significance levels of microarray results between non amplified (NA) and amplified (PA) RNA samples were calculated using the Mann-Whitney U-test (*P* \< .05, means differecially expressed). The average signal intensity of PA/NA was calculated as fold change (FC). Unsupervised and supervised hierarchical cluster analyses of all 22.215 probe sets (HG-U 133A, Affymetrix) were performed (Spotfire, Decision Site, Somerville, USA). Differences in signal intensity of microarray results between NA versus PA were analysed regarding sequence length and chromosomal localization. Pearson correlation of signals and detection *P*-values from microarray results between NA versus PA were investigated.

Moreover, validation of amplification bias was done for 22.215 gene expression values (HG-U133A, Affymetrix) for 31 amplified RNA samples of colon carcinoma samples versus 24 not amplified RNA samples of colon carcinoma samples, all stage UICC III. The Pearson correlation was calculated and the mean expression values and standard deviation (log~2~) of 50 predictive genes for lymphatic metastasis recently described have been compared \[[@B12]\]. For validation purpose gene expression measures were computed with the Robust Multichip Average (RMA) method described in Irizarry et al. \[[@B12]\] and implemented in the R-function just RMA of the Bioconductor R package affy. The statistical analysis was performed with the open-source software R, Version 2.6.1.

3. Results {#sec3}
==========

3.1. Comparability of Amplified and Non Amplified RNA {#sec3.1}
-----------------------------------------------------

In the amplified test set 200 ng of RNA was used as the starting yield. Two rounds of amplification of RNA resulted in sufficient amounts of cRNA with good quality for microarray hybridization. The correlation of the microarray signals between non amplified and amplified RNA reached 86%--91%. The detection *P*-values of the microarray data correlated in 75%--81% ([Table 1](#tab1){ref-type="table"}). An unsupervised hierarchical cluster analysis including all 22.283 probe sets from the GeneChips separated all unamplified from the preamplified RNA samples ([Figure 2](#fig2){ref-type="fig"}). All samples were correctly classified regarding the method of RNA pretreatment. In the statistical analysis (Mann-Whitney U-test, *P* \< .05) 5.725 significantly differentially expressed genes between non amplified and amplified RNA samples could be identified. In 1.182 probe sets of the microarray a significantly elevated signal intensity of amplified versus non amplified samples could be detected. In 4.543 probe sets significantly lower signal intensity between amplified versus non amplified RNA could be detected. The fold change (PA/NA) of the mean signals was between 8 (bicaudal-D (BICD) mRNA) and 13 (myosin I × b (MYO9b) mRNA). Several ribosomal RNA (e.g., 18S rRNA gene) which were included on the microarrays as internal control could be detected with a fold change of 273 between amplified vs. non amplified samples. In 36% RNA with increased FC and in 32% RNA with a decreased FC had a sequence length between 1000--19000 bp. In 5% RNA with increased FC and in 1% RNA with a decreased FC had a sequence length \>300000 bp ([Figure 3(a)](#fig3){ref-type="fig"}). Thirteen per cent of genes with an increased FC were located on chromosome 1; 10% on chromosome 17; 9% on chromosome 6, and 8% on chromosome 2. Eleven per cent of genes with decreased FC were located on chromosome 19; 9% were located on chromosome 2, chromosome 7, and chromosome 12, and 8% on chromosome 16 ([Figure 3(b)](#fig3){ref-type="fig"}).

3.2. Influence of RNA Amplification on Colorectal Cancer Specific Genes {#sec3.2}
-----------------------------------------------------------------------

Various genes which have been recently described participating in carcinogenesis and tumour progression in colorectal carcinomas could be identified with significantly different signals between amplified and non amplified RNA samples (e.g., WNT3, APC, and VEGF). VEGFB had a decreased FC of −5 and the APC gene −4. Several genes involved in the cell cycle (CDC5, CDC6, CDC2, CDC25C, CDC25A) were found with significantly different microarray signals with an FC between 3 and −4. Matrix metalloproteinases as MMP-11, MMP14, and MMP 15 showed decreased FC between −4 and −9 ([Table 2](#tab2){ref-type="table"}).

3.3. Validation of Amplification Bias {#sec3.3}
-------------------------------------

The Spearman correlation of 22.115 probe sets (Affymetrix HG-U133A) between 31 amplified RNA samples versus 24 not amplified RNA samples of colon carcinomas stage UICC III was 0.8 ([Figure 4](#fig4){ref-type="fig"}). Comparing the mean microarray signals of 50 recently described genes predictive for lymphatic metastasis only in one case an equal value could be detected (210701_at). The standard deviation in this case was less high without RNA amplification. In most other genes substantially differences were identified ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

Gene expression profiling has become an attractive tool for tissue typing and prognostic evaluations in cancer research. For colorectal carcinoma several gene profiles dividing healthy mucosa from tumours and for prognostic classification could be identified \[[@B5], [@B7], [@B12]--[@B15]\]. Nevertheless there is only a limited overlap in the described gene profiles in most of these studies \[[@B5]\]. One reason for this finding might be the fact that there is a brought variability of applied techniques used during the analysis. Regarding the methods of tissue handling and isolation, RNA preparation, and microarray hybridization, various distributive factors may influence the results. Especially, when only small amounts of tissue can be harvested or only limited amounts of tissue are available, the yield of RNA might not be sufficient for microarray hybridization. Preprocessing of the RNA by amplification becomes indispensable. Whether samples of amplified RNA can be compared to samples with non amplified RNA is still discussed controversially. For the amplified probes, we used the linear amplification technique which is based on a double-stranded cDNA synthesis with an oligo-dT primer coupled to the T7 RNA polymerase promoter followed by an *in vitro* transcription into aRNA by T7 RNA polymerase \[[@B16]\]. This is an established technique used for RNA amplification procedures during microarray experiments \[[@B17]--[@B19]\]. During two rounds of amplification enough RNA in sufficient quality could be generated for microarray hybridization which supports the reliability of the method. The Affymetrix (Santa Clara, USA) GeneChip technology provides standardized protocols for microarray procedures on a commercial platform which is frequently used in gene expression profiling regarding colorectal tumours \[[@B4], [@B14], [@B20]--[@B24]\]. Using unsupervised hierarchical cluster analysis of our microarray results we observed a separation of two groups respecting the RNA pretreatment. We identified 5.725 significantly differentially expressed genes between non amplified and amplified RNA samples. As amplified and non amplified RNA referred to the same samples no separation in clusters should have been occurred. The cluster results and the identification of significantly different expressed genes demonstrate an amplification bias between native and amplified RNA. The correlation of microarray signal NA versus PA was between 86--91%. This amplification bias could be validated in a cohort of 55 RNA samples either amplified or not amplified from colon carcinoma samples (stage UICC III). The correlation of 22.115 probe set signals did reached only 80% and the comparison of 50 genes involved in lymphatic metastasis varied substantially. If the same labelled cRNA is hybridized twice to microarrays the correlation of signals is 99%. When two cRNA samples are generated from the same mRNA and hybridized to microarrays, the correlation of signals is about 99% as well. Signal correlations of 97% were reached with two separate RNA isolations and microarray hybridizations of one and the same tumour probe (data not published). Behind these findings, the identified differences between amplified and non amplified RNA are relevant. Analysing the reasons for these findings we detected that sequences with a length of bp 1000--19000 are mainly affected by differential signal intensity. This may be explained due to the more frequent amplification of shorter transcripts which may be dependent on the amount of amplification rounds. A connection of sequences located on specific chromosomes could not be identified. These findings are supported by previous studies which identified a correlation between amplification rounds and comparability between native and amplified RNA \[[@B18]\]. The detected alterations during RNA amplification are important, because several genes of interest involved in carcinogenesis (e.g., APC, VEGF) and tumour progression (e.g., CDC2, MMPs) were affected. When amplified and non amplified RNA are compared in the same microarray study false positive results might occur. Therefore, amplified and non amplified RNA should not be compared during microarray investigations. These findings have already been suspected previously, but have not been demonstrated in detail so far \[[@B18], [@B19]\].

5. Conclusion {#sec5}
=============

Amplification of RNA by the T7-IVT is an elegant method to generate RNA in good quality and sufficient yield for microarray hybridization from as less as 200 ng of starting RNA. Nevertheless during amplification alterations occur which lead to an amplification bias compared to non amplified RNA. For this reason the microarray results of amplified and non amplified RNA samples should not be compared within the same study.
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![Experimental procedure. RNA was isolated from tumours after CMD; one part of the RNA underwent amplification and the other part was hybridized without preamplification to microarrays.](JBB2009-837170.001){#fig1}

![Unsupervised (a) and supervised (b) hierarchical cluster analysis of microarray results from non amplified and amplified RNA samples from colorectal carcinoma samples.](JBB2009-837170.002){#fig2}

![Differences in total gene expressions between non amplified (NA) versus amplified (PA) RNA, regarding (a) sequence length of genes and (b) chromosomal localization.](JBB2009-837170.003){#fig3}

![Comparison of mean signals (HG-U 133A, Affymetrix) between RNA samples of 31 colon carcinomas amplified and 24 RNA samples of colon carcinomas not amplified prior to microarray hybridization.](JBB2009-837170.004){#fig4}

###### 

Pearson correlations of microarray signals and detection *P*-values between non amplified (NA) and amplified (PA) RNA samples from four colorectal carcinoma specimens. The RNA was isolated from identical samples and underwent either amplification or no amplification prior to microarray hybridization.

  Samples            Signals   Detection *P*-value
  ------------------ --------- ---------------------
  1 NA versus 1 PA   0.91      .81
  2 NA versus 2 PA   0.89      .75
  3 NA versus 3 PA   0.86      .79
  4 NA versus 4 PA   0.91      .81

###### 

Different gene expression values of cancer specific genes between non amplified (NA) and amplified (PA) RNA samples from colorectal carcinoma samples.

  Affy           Gb          Bases       Anotation                                                          Avg. Signals NA   Avg. Signals PA   FC PA/NA   *P*
  -------------- ----------- ----------- ------------------------------------------------------------------ ----------------- ----------------- ---------- -----
  221455_s\_at   NM_030753   56038       Wingless-type MMTV integration site family, member 3 (WNT3).       20                78                4          .04
  212447_at      AF161402    23,589      HSPC284 mRNA, partial cds.                                         2480              9611              4          .01
  201111_at      NM_001253   50,649      Brain cellular apoptosis susceptibility protein (CSE1).            2568              7431              3          .01
  209056_s\_at   NM_001253   62,329      CDC5 (cell division cycle 5, S. pombe, homolog)-like (CDC5L).      1399              3861              3          .01
  206458_s\_at   NM_024494   54,746      Wingless-type MMTV integration site family, member 2B (WNT2B).     72                177               2          .01
  207149_at      L33477      1,102,757   Br-cadherin mRNA, complete cds.                                    35                84                2          .04
  204731_at      NM_003243   225,660     Transforming growth factor, beta receptor III (TGFBR3).            602               1336              2          .04
  219226_at      NM_016507   73,062      CDC2-related protein kinase 7 (CrkRS).                             555               1131              2          .01
  217366_at      Z37994      3620        Alpha E-catenin pseudogene.                                        30                6                 2          .04
  208504_x\_at   NM_018931   3321        Protocadherin beta 11 (PCDHB11).                                   33                11                2          .04
  201069_at      NM_004530   27,516      Matrix metalloproteinase 2 (MMP2).                                 1528              887               −2         .04
  203968_s\_at   NM_001254   15,268      Cell division cycle 6 (CDC6).                                      624               338               −2         .01
  203918_at      NM_002587   25,296      Protocadherin 1 (PCDH1).                                           544               290               −2         .04
  208756_at      U36764      9235        TGF-beta receptor interacting protein 1.                           4451              2355              −2         .01
  210838_s\_at   L17075      15,944      TGF-b superfamily receptor type I.                                 277               127               −2         .01
  206943_at      NM_004612   49,063      Transforming growth factor, beta receptor I (TGFBR1).              331               150               −2         .01
  212143_s\_at   BF340228    9028        Insulin-like growth factor binding protein 3.                      1192              462               −3         .01
  202039_at      NM_004740   2089        TGFB1-induced antiapoptotic factor 1 (TIAF1).                      1000              371               −3         .01
  203214_x\_at   NM_001786   18927       Cell division cycle 2, G1 to S and G2 to M (CDC2).                 3181              1174              −3         .01
  160020_at      Z48481      11,011      Membrane-type matrix metalloproteinase 1 (MMP1).                   1258              437               −3         .01
  217010_s\_at   AF277724    46,558      Cell division cycle 25C splice variant 3 (CDC25C).                 211               61                −3         .01
  204696_s\_at   NM_001789   31,134      Cell division cycle 25A (CDC25A).                                  123               34                −4         .01
  203527_s\_at   NM_000038   108,353     Adenomatosis polyposis coli (APC).                                 85                23                −4         .01
  210287_s\_at   U01134      192,877     Soluble vascular endothelial cell growth factor receptor (sflt).   143               37                −4         .01
  203878_s\_at   NM_005940   11,468      Matrix metalloproteinase 11 (stromelysin 3) (MMP11).               1546              400               −4         .01
  203365_s\_at   NM_002428   21,524      Matrix metalloproteinase 15 (membrane-inserted) (MMP15).           388               93                −4         .04
  203683_s\_at   NM_003377   3994        Vascular endothelial growth factor B (VEGFB).                      422               78                −5         .01
  217279_x\_at   X83535      11,011      Membrane-type matrix Metalloproteinase (MMP14).                    244               27                −9         .01
  204380_s\_at   M58051      15,565      Fibroblast growth factor receptor (FGFR3).                         224               25                −9         .01
  207334_s\_at   NM_003242   87,641      Transforming growth factor, beta receptor II (TGFBR2).             323               15                −16        .01

###### 

Comparison of mean signals and standard deviation (sdv) of genes which were recently described as predictive for lymphatic metastasis in colorectal carcinomas \[[@B12]\], between 31 amplified RNA samples of colon carcinomas and 24 RNA samples of colon carcinomas not amplified prior to microarray hybridization.

  Group                                                                                                    Colon carcinoma   Colon carcinoma                 
  -------------- ----------- ---------- --------- -------------------------------------------------------- ----------------- ----------------- ------------- -------------
  ProbeSet ID    gb          Gene       Bases     fold change log~2~ mean amplified versus non amplified   log~2~ mean       log~2~ sdev       log~2~ mean   log~2~ sdev
                                                                                                                                                             
  205433_at      NM_000055   BCHE       64562     1.05                                                     4.36              0.71              4.16          0.21
  211044_at      BC006333    TRIM14     49,926    0.8                                                      3.37              0.18              4.22          0.24
  37547_at       U85995      PTHB1      476,529   1.32                                                     5.63              0.61              4.25          0.17
  215973_at      AF036973    HCG4P6     1060      0.89                                                     4.07              0.36              4.56          0.21
  214376_at      AI263044    EST        363       0.99                                                     4.53              0.36              4.55          0.14
  216489_at      AB046836    TRPM3      911,872   0.75                                                     3.46              0.16              4.62          0.2
  211201_at      M95489      FSHR       192,237   0.76                                                     3.55              0.21              4.65          0.16
  214068_at      AF070610    BEAN       56,130    0.74                                                     3.45              0.41              4.66          0.21
  216063_at      N55205      HBBP1      1742      0.79                                                     3.75              0.21              4.72          0.24
  219791_s\_at   NM_024748   FLJ11539   11,373    0.77                                                     3.67              0.43              4.77          0.2
  209353_s\_at   BC001205    SIN3B      50,947    0.92                                                     4.37              0.23              4.77          0.29
  211381_x\_at   AF168617    SPAG11     15,917    0.76                                                     3.63              0.22              4.78          0.35
  207021_at      NM_007009   ZPBP       155,788   0.74                                                     3.57              0.2               4.85          0.17
  220227_at      NM_024883   CDH4       684,743   0.74                                                     3.77              0.19              5.12          0.38
  210701_at      D85939      CFDP1      139,780   1                                                        5.12              0.42              5.12          0.22
  220156_at      NM_024593   EFCAB1     11,825    0.76                                                     4.04              0.17              5.32          0.28
  209883_at      AF288389    GLT25D2    101,898   0.89                                                     4.67              0.77              5.25          0.19
  207031_at      NM_001189   BAPX1      3661      1.04                                                     5.54              0.67              5.32          0.29
  206885_x\_at   NM_022559   GH1        1636      0.76                                                     4.14              0.27              5.47          0.25
  212963_at      BF968960    TM2D1      44,379    0.83                                                     4.6               0.41              5.55          0.27
  207897_at      NM_001883   CRHR2      46,857    0.81                                                     4.59              0.16              5.67          0.32
  222083_at      AW024233    GLYAT      23,218    0.64                                                     3.69              0.21              5.72          0.37
  214149_s\_at   AI252582    ATP6V0E    51,138    0.86                                                     5.07              0.49              5.87          0.58
  220332_at      NM_006580   CLDN16     22,493    0.82                                                     4.71              0.25              5.75          0.21
  220944_at      NM_020393   PGLYRP4    18,721    0.78                                                     4.57              0.27              5.84          0.52
  219170_at      NM_024333   FSD1       19,171    0.91                                                     5.35              0.24              5.9           0.36
  221113_s\_at   NM_016087   WNT16      15,738    1.03                                                     6.15              0.17              5.95          0.28
  221431_s\_at   NM_030959   OR12D3     948       0.68                                                     4.08              0.23              6.03          0.31
  207936_x\_at   NM_006604   RFPL3      6277      0.64                                                     3.96              0.36              6.16          0.47
  204303_s\_at   NM_014772   KIAA0427   324,158   0.99                                                     6.01              0.31              6.09          0.17
  210272_at      M29873      CYP2B7P1   26,394    0.74                                                     4.69              0.23              6.35          0.38
  207984_s\_at   NM_005374   MPP2       32,387    0.64                                                     4.07              0.25              6.36          0.26
  208227_x\_at   NM_021721   ADAM22     262,753   0.69                                                     4.55              0.31              6.56          0.35
  213847_at      NM_006262   PRPH       4997      0.84                                                     5.63              0.33              6.71          0.42
  215544_s\_at   AL121891    UBOX5      14,320    0.85                                                     5.83              0.23              6.85          0.31
  336_at         D38081      TBXA2R     12,155    0.74                                                     5.03              0.24              6.84          0.28
  209402_s\_at   AF047338    SLC12A4    24,296    1                                                        6.97              0.26              7             0.25
  221629_x\_at   AF151022    LOC51236   2948      0.83                                                     6.04              0.58              7.29          0.5
  219071_x\_at   NM_016458   C8orf30A   2948      1.03                                                     8.12              0.71              7.92          0.52
  56829_at       H61826      NIBP       726,091   0.82                                                     6.83              0.27              8.29          0.3
  205835_s\_at   AW975818    YTHDC2     81,572    0.9                                                      4.11              0.17              4.59          0.19
  213254_at      N64803      TNRC6B     290,992   0.93                                                     6.15              0.23              6.65          0.38
  34764_at       D21851      LARS2      160,261   1.01                                                     7.13              0.63              7.04          0.51
  209711_at      N80922      SLC35D1    50,402    1.32                                                     10.2              0.52              7.73          0.45
  203073_at      NM_007357   COG2       51,491    1                                                        8.11              0.51              8.07          0.3
  209174_s\_at   BC000978    FLJ20259   64,363    1.07                                                     8.71              0.32              8.17          0.25
  221884_at      BE466525    EVI1       64,236    1.25                                                     10.56             0.66              8.46          0.46
  218160_at      NM_014222   NDUFA8     15,762    1.22                                                     11.3              0.38              9.24          0.47
  201386_s\_at   AF279891    DHX15      57,098    1.08                                                     10.44             0.66              9.64          0.52
  202753_at      NM_014814   PSMD6      13,281    1.14                                                     11.46             0.44              10.03         0.46

[^1]: Recommended by Yataro Daigo
